ResMed reports continued growth in second quarter of 2016

ResMed has stated its satisfaction with the strong financial results it was able to deliver during the second quarter of 2016.

During the three months ending on December 31st 2015, the company achieved a revenue total of $454.5 million (317.21 million pounds), up by seven percent year on year, or 13 percent on a constant currency basis.

Its performance in the Americas region was a key driver of the company's performance during the period, with strong demand for its Air Solutions cloud-based software, AirSense devices and AirFit patient interface systems all observed.

The firm has also expanded its respiratory care business into the field of long-term oxygen therapy through its recent agreement to purchase the Texas-based medical technology firm Inova Labs.

A developer of long-term oxygen therapy solutions for the treatment of chronic obstructive pulmonary disease, Inova Labs' portfolio includes offerings such as the lightweight, portable oxygen concentrator LifeChoice Activox.

Mick Farrell, ResMed's chief executive officer, said: "We remain focused on delivering strong long-term growth from our sleep-disordered breathing and respiratory care businesses. Our team continued to deliver double-digit constant currency growth this quarter."